Navigation Links
Uroplasty Announces Delay in Filing Form 10-K
Date:6/14/2013

MINNEAPOLIS, June 14, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative products to treat voiding dysfunctions, announced today that it will delay the filing of its Annual Report on Form 10-K for the year ended March 31, 2013, until the completion of a review of its internal control over financial reporting.

In connection with a review of employee expense reimbursements conducted after the end of the fiscal year, the Company uncovered limited issues related to the internal controls surrounding the employee expense reimbursement approval process. The Company preliminarily concluded that these issues were unlikely to materially affect its financial statements. However, as a result of this review, the Company later uncovered issues in internal control related to the recognition of orders and the payment of sales commissions at the end of fiscal quarters. The Company concluded that further review was advisable. The review is being conducted at the direction of the Audit Committee of the Board of Directors of the Company, with the assistance of independent advisors. 

Based upon facts available, the Company does not currently believe that a material revision of its previously released earnings is likely. However, the review of internal control issues has not been completed and the Company is unable at this time to fully assess the potential impact on its financial statements.

The Company has placed Mahedi Jiwani, its Chief Financial Officer, on administrative leave pending completion of the internal control review. 

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results, including further facts or issues that may be uncovered during the course of the review and investigation referenced in this press release.

CONTACT:
Rob Kill, Interim Chief Executive Officer
952-426-6140


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2013 Financial Results
2. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Wisconsin Physicians Services
3. Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013
4. Uroplasty Announces CEO Resignation
5. Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference
6. Uroplasty Announces Executive Changes In US Sales Organization
7. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
8. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
9. Uroplasty To Participate In Two Upcoming Investor Conferences
10. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
11. Uroplasty To Participate In Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the field ... currently accepting new patients at their practice for these custom clear aligners. These qualified ... why they offer the latest in modern dental techniques to ensure that all their ...
(Date:6/20/2017)... ... June 20, 2017 , ... Many ... their regulatory principles, the research team developed expressRNA, a web platform encompassing computational ... This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, one ... the partner of choice by Amtrak to fulfill several projects in various Northeast ... long-distance intercity service in the contiguous United States. Security Executives at the company ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets this ... France’s Seine River and designed small enough to dock directly in Paris. With The ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of Momkus McCluskey Roberts ... president of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on ... the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was ...
Breaking Medicine News(10 mins):